Zumsteg, Z. S., Morse, N., Krigsfeld, G., Gupta, G., Higginson, D. S., Lee, N. Y., . . . Baselga, J. (2015). Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res.
استشهاد بنمط شيكاغوZumsteg, Zachary S., et al. "Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations." Clin Cancer Res 2015.
MLA استشهادZumsteg, Zachary S., et al. "Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations." Clin Cancer Res 2015.